Premium
Characterization of B16 mFL‐expanded DC populations in peripheral and GI lymphoid tissues
Author(s) -
Papenfuss Tracey L.,
Singh Sanjay,
Whitacre Caroline C.,
Boyaka Prosper N.
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.853.14
Subject(s) - cd11c , cd86 , spleen , in vivo , mhc class ii , immunology , lymphatic system , t cell , peripheral , microbiology and biotechnology , medicine , phenotype , chemistry , biology , immune system , gene , biochemistry
In vivo expansion of murine DCs can be accomplished by either human Flt3‐ligand (hFL) or murine FL (mFL). Recent work shows that mFL DCs more accurately model resting DCs. Furthermore, while mFL‐secreting B16 cells (B‐mFL) are used for in vivo expansion, it remains unclear whether tumor burden influences the DC generation. In this study, we evaluated the kinetics/phenotype of mFL DCs in vivo in peripheral and GI lymphoid tissues. Injection of 1x106 B‐mFL cells rapidly expanded DCs in both the peripheral lymph nodes (PLN) and spleen (SPL), which were markedly increased in size. MHC class II expression (PLN and SPL) and CD86 (PLN) decreased over time, as well as, the number of CD8a+ DCs within the SPL. We then refined the use of B‐mFL cells with mitomycine (Mit) treatment to prevent tumor growth. Mice injected with 2x106 B‐mFL cells (+) Mit showed increased weight of SPL (55–90%) and mesenteric LN (MLN) (20–30%). Cell yield was increased in the PLN and MLN (5–6x over controls) with a 1.5–2 fold increase in SPL and Peyer's patches (PP). mFL increased the yield of CD11c+ DCs most dramatically in the MLN (5–7x) and PLN (3–5x) and less so in the SPL (1.2–1.9 fold) with minimal effect on PP DCs. These studies demonstrate that B‐mFL cells (+)Mit is a viable means to expand DCs in peripheral and GI lymphoid tissues. Supported in part by NMSS FG1555‐A‐1 and NIH K01RR022198‐01A1.